High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis

Clinical Infectious Diseases

Volumn 54, Issue 3, 2012, Pages 347-354

  Durante Mangoni, Emanuele ^a   Casillo, Roberta ^a   Bernardo, Mariano ^a   Caianiello, Cristina ^a   Mattucci, Irene ^a   Pinto, Daniela ^a   Agrusta, Federica ^a   Caprioli, Roberta ^a   Albisinni, Rosina ^a   Ragone, Enrico ^a   Utili, Riccardo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIARRHYTHMIC AGENT; CASPOFUNGIN; CEFTRIAXONE; CREATINE KINASE; DAPTOMYCIN; DIURETIC AGENT; GENTAMICIN; INOTROPIC AGENT; LINEZOLID; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL HEART PACEMAKER; BACTERIAL ENDOCARDITIS; BLOOD CULTURE; CARDIAC IMPLANTABLE ELECTRONIC DEVICE; CARDIOVASCULAR EQUIPMENT; CLINICAL ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; CREATINE KINASE BLOOD LEVEL; DEFIBRILLATOR; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; KIDNEY FUNCTION; LUNG EMBOLISM; LUNG INFECTION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OPEN HEART SURGERY; PRIORITY JOURNAL; SIDE EFFECT; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; TRICUSPID VALVE DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; ENDOCARDITIS, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PACEMAKER, ARTIFICIAL; PROSTHESIS-RELATED INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; TREATMENT OUTCOME;

EID: 84855879417     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir805     Document Type: Article

References (23)

1. Jarcho JA. Biventricular pacing. N Eng J Med 2006;355:288-94. (Pubitemid 44079343)
2. Uslan DZ, Tleyjeh IM, Baddour LM, et al. Temporal trends in permanent pacemaker implantation: a population-based study. Am Heart J 2008;155:896-903.
3. Cabell CH, Heidenreich PA, Chu VH, et al. Increasing rates of cardiac device infections among Medicare beneficiaries 1990-1999. Am Heart J 2004;147:582-6. (Pubitemid 38900441)
4. Voigt A, Shalaby A, Saba S. Rising rates of cardiac rhythm management device infections in the United States: 1996 through 2003. J Am Coll Cardiol 2006;48:590-1. (Pubitemid 44093958)
5. Uslan DZ, Sohail MR, St Sauver JL, et al. Permanent pacemaker and implantable cardioverter-defibrillator infection: a population-based study. Arch Intern Med 2007;167:669-75. (Pubitemid 46598459)
6. Voigt A, Shalaby A, Saba S. Continued rise in rates of cardiovascular implantable electronic device infections in the United States: temporal trends and causative insights. Pacing Clin Electrophysiol 2010;33:414-9.
7. Baddour LM, Epstein AE, Erickson CC, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 2010;121:458-77.
8. Utili R, Durante-Mangoni E, Tripodi MF. Infection of intravascular prostheses: how to treat other than surgery. Int J Antimicrob Agents 2007;30(Suppl 1): S42-50.
9. Fowler VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653-65.
10. Raad I, Hanna H, Jiang Y, et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007;51:1656-60. (Pubitemid 46744141)
11. Stewart PS, Davison WM, Steenbergen JN. Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm. Antimicrob Agents Chemother 2009;53:3505-7.
12. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006;50:3245-9. (Pubitemid 44527494)
13. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. Safety and clinical outcomes when utilizing high-dose (≥8 mg/kg) daptomycin therapy. Ann Pharmacother 2009;43:1211-9.
14. Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009;49:177-80.
15. Katz DE, Lindfield KC, Steenbergen JN, et al. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract 2008;62:1455-64.
16. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 1.3. 2011. Available at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Disk- test-documents/EUCAST-breakpoints-v1.3-pdf.pdf Accessed 29 June 2011.
17. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 suppl 1): S19.
18. Durante-Mangoni E, Casillo R, Pinto D, et al. Heart transplantation during active infective endocarditis: case report and review of the literature. Transplant Proc 2011;43:304-6.
19. Sohail MR, Uslan DZ, Khan AH, et al. Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. J Am Coll Cardiol 2007;49:1851-9. (Pubitemid 46661104)
20. Bae IG, Federspiel JJ, Mirò JM, et al. Heterogeneous vancomycinintermediate susceptibility phenotype in bloodstream methicillinresistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J Infect Dis 2009;200:1355-66.
21. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-402. (Pubitemid 38747480)
22. Soriano A, Marco F, Martìnez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200. (Pubitemid 351269157)
23. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166:2138-44. (Pubitemid 44631403)